Eckert & Ziegler Strahlen- und Medizintechnik AG / Analyst ratings
Price targets
Analyst ratings
2 analysts rated this company in the past 90 days. The average target price is €44.50, this is a change of +158.4% compared to the current price.
-
Berenberg maintains Eckert & Ziegler at 'Buy' - target 24 euros
HAMBURG (dpa-AFX Analyst) - Private bank Berenberg has maintained its "Buy" rating for Eckert & Ziegler with a price target of €24. CEO Harald Hasselmann has reinforced his positive assessment of the isotope specialist, Benjamin Thielmann wrote after the second day of the Berenberg conference on Tuesday./ag/tav
Publication of the original study: September 23, 2025 / 11:22 a.m. / GMT
First distribution of the original study: Date not specified in study / Time not specified in study / Time zone not specified in study
Note: Information on the disclosure obligation in the event of conflicts of interest within the meaning of Section 85 (1) of the German Securities Trading Act (WpHG), Article 20 of Regulation (EU) No. 596/2014 for the aforementioned analyst firm can be found at http://web.dpa-afx.de/offenlegungspflicht/offenlegungs_pflicht.html.
-
Berenberg starts Eckert & Ziegler with 'Buy' - target 24 euros
HAMBURG (dpa-AFX Analyst) - Private bank Berenberg has initiated its "Buy" rating on Eckert & Ziegler shares, setting a price target of €24. The medical and measurement technology supplier is the world's leading provider of radioactive isotopes and radiotherapeutic devices, Benjamin Thielmann wrote in his buy recommendation issued Tuesday. Its strong market position should lead to average annual profit growth of 10 percent for the period 2025 to 2028, with the net profit margin expected to reach around 18 percent by 2028./edh/ag
Publication of the original study: September 8, 2025 / 5:00 PM / GMT
First distribution of the original study: Date not specified in study / Time not specified in study / Time zone not specified in study
Note: Information on the disclosure obligation in the event of conflicts of interest within the meaning of Section 85 (1) of the German Securities Trading Act (WpHG) and Article 20 of Regulation (EU) No. 596/2014 for the aforementioned analyst firm can be found at http://web.dpa-afx.de/offenlegungspflicht/offenlegungs_pflicht.html.
-
Hauck Aufhäuser IB lowers target for Eckert & Ziegler Euro - 'Hold'
HAMBURG (dpa-AFX Analyser) - Hauck Aufhäuser Investment Banking has lowered the price target for Eckert & Ziegler from 70 to 65 euros and left the rating at "Hold". Since the company's earnings growth could slow, the risk-reward ratio of the shares appears unattractive, wrote Alexander Galitsa in a study published Monday./rob/mis/bek
Publication of the original study: August 11, 2025 / 8:11 a.m. / Time zone not specified in the study
First distribution of the original study: August 11, 2025 / 8:23 a.m. / Time zone not specified in the study
Note: Information on the disclosure obligation in the event of conflicts of interest within the meaning of Section 85 (1) of the German Securities Trading Act (WpHG) and Article 20 of Regulation (EU) No. 596/2014 for the aforementioned analyst firm can be found at http://web.dpa-afx.de/offenlegungspflicht/offenlegungs_pflicht.html.
-
Hauck Aufhäuser IB lowers Eckert & Ziegler to 'Hold' - Target high
HAMBURG (dpa-AFX Analyst) - Hauck Aufhäuser Investment Banking has raised its price target for Eckert & Ziegler shares from €66 to €70, but downgraded the stock from "Buy" to "Hold" following the recent strong price performance. Alexander Galitsa wrote on Wednesday regarding his reclassification that the shares of the medical and radiation technology company are due a pause. In the short term, the risk-reward ratio appears less convincing./ajx/ag
Publication of the original study: May 21, 2025 / 8:01 a.m. / CET First distribution of the original study: May 21, 2025 / 8:15 a.m. / CET
Note: Information on the disclosure obligation in the event of conflicts of interest within the meaning of Section 85 (1) of the German Securities Trading Act (WpHG) and Article 20 of Regulation (EU) No. 596/2014 for the aforementioned analyst firm can be found at http://web.dpa-afx.de/offenlegungspflicht/offenlegungs_pflicht.html.
-
Hauck Aufhäuser IB leaves Eckert & Ziegler on 'Buy', target 66 euros
HAMBURG (dpa-AFX Analyser) - Hauck Aufhäuser Investment Banking has maintained its rating for Eckert & Ziegler at "Buy" with a price target of 66 euros. As a supplier of radioactive components, the company is benefiting greatly from the increasing use of radioligand therapy with Novartis' Pluvicto, analyst Alexander Galitsa said in his commentary published Tuesday regarding the expanded approval of Pluvicto./ag/ajx
Publication of the original study: April 1, 2025 / 9:01 a.m. / CET
First distribution of the original study: April 1, 2025 / 9:01 a.m. / CET
Note: Information on the disclosure obligation in the event of conflicts of interest within the meaning of Section 85 (1) of the German Securities Trading Act (WpHG) and Article 20 of Regulation (EU) No. 596/2014 for the aforementioned analyst firm can be found at http://web.dpa-afx.de/offenlegungspflicht/offenlegungs_pflicht.html.
-
Hauck Aufhäuser IB leaves Eckert & Ziegler on 'Buy', target 55 euros
HAMBURG (dpa-AFX Analyst) - Hauck Aufhäuser Investment Banking has maintained its "Buy" rating for Eckert & Ziegler with a price target of €55. The order book appears promising, wrote analyst Alexander Galitsa in his review of the final quarterly figures released on Monday. The company is on track to meet its annual targets. /ag/zb
Publication of the original study: November 18, 2024 / 8:28 a.m. / CET
First distribution of the original study: November 18, 2024 / 8:28 a.m. / CET
Note: Information on the disclosure obligation in the event of conflicts of interest within the meaning of Section 85 (1) of the German Securities Trading Act (WpHG) and Article 20 of Regulation (EU) No. 596/2014 for the aforementioned analyst firm can be found at http://web.dpa-afx.de/offenlegungspflicht/offenlegungs_pflicht.html.